Progress in acute myeloid leukaemia treatment is occurring at an unprecedented pace. The
past decade has witnessed an increasingly improved scientific understanding of the …

Measurable residual disease (MRD) assessment in acute myeloid leukemia (AML) has an
established role in disease prognostication, particularly in guiding decisions for …

Cytogenetics has long represented a critical component in the clinical evaluation of
hematologic malignancies. Chromosome banding studies provide a simultaneous snapshot …

Dear Editor, Poly (ADP-ribose) polymerase (PARP) inhibitors interact with DNA at single-
strand breaks, prevent repair, and generate irreparable double-strand breaks that lead to …

Dear Editor, Clonal cytopenia (s) of undetermined significance (CCUS) is defined by the
presence of the somatic mutation (s) of genes associated with myeloid neoplasms, with …

Assessment of internal tandem duplications in FLT3 (FLT3-ITDs) and their allelic ratio (AR)
is recommended by clinical guidelines for diagnostic workup of acute myeloid leukemia and …

FMS-like tyrosine kinase 3 (FLT3) mutations are detected in approximately 20–30% of
patients with acute myeloid leukemia (AML), with the presence of a FLT3 internal tandem …

FMS-like tyrosine kinase 3 (FLT3) is one of the most closely studied genes in blood
diseases. Numerous methods have been adopted for analyses, mainly in acute myeloid …

In the era of personalized medicine, information on molecular change at the gene level is
important for patient care. Such information has been used for disease classification …

FLT3 internal tandem duplications (ITDs) are found in approximately one-third of patients
with acute myeloid leukemia and have important prognostic and therapeutic implications …